Research Interest, Education & Publications

photo of Dan Rudic, PhD

Dan Rudic, PhD

  • Professor
  • Pharmacology & Toxicology


Research & Education Building, CB 3620

Office phone icon:  706-721-7649
Lab CB 2602 phone icon:  706-721-7662


Members of the Lab



Our main interest is how the blood vessel becomes diseased and how it drives disease.  Firstly, we are interested in how disease progresses in blood vessels themselves, by studying the process of how arteries ‘rebuild’ themselves.  This process is called vascular remodeling.  In the small picture, we want to determine which molecules are most robustly increasing and decreasing during remodeling, with the goal to identify new factors that could be targets to treating disease.  The blood vessels (arteries) have different cell types and layers, but our cellular focus is on the inner-most blood vessel lining, the endothelial cell layer. The molecular targets in the endothelial cell we are focused on include bHLH transcription factors that control circadian rhythm (Bmal1) and endothelial identity (Tal1).  This project may relate to vascular diseases, such as atherosclerosis.  A second, emerging area of interest for us, is how blood vessels are influenced by aging and how arteries interact with the brain in its memory center (the hippocampus).   This may be relevant to diseases such as Alzheimer’s disease. Our studies are performed in mice, where we induce remodeling by a surgical ligation of the carotid artery, and we study histopathology and signaling (via focused and profiling approaches) in the vessels and the brain.


08/2005     Postdoctoral                     University of Pennsylvania                          

12/2000     PhD in Pharmacology     Yale University

06/1996     MS in Pharmacology       Yale University                          

05/1991     BS in Biology                    Temple University


2019 - Present     Professor, Medical College of Georgia, Department of Pharmacology and Toxicology


Board of Atherosclerosis and Vascular Medicine (specialty section of Frontiers in Cardiovascular Medicine)


         Ad hoc NIDDK DDK-B, study section
         AHA Career Development Award Vascular 1 review panel (2021)


Hermida RC, Smolensky MH, Balan H, Castriotta RJ, Crespo JJ, Dagan Y, El-Toukhy S, Fernandez JR, FitzGerald GA, Fujimura A, Geng YJ, Hermida-Ayala RG, Machado AP, Menna-Barreto L, Mojon A, Otero A, Rudic RD, Schernhammer E, Skarke C, Steen TY, Young ME, Zhao X. Guidelines for the design and conduct of human clinical trials on ingestion-time differences - chronopharmacology and chronotherapy - of hypertension medications. Chronobiology international. 2021;38:1-26

Xu Y, Pi W, Rudic RD. Old and new roles and evolving complexities of cardiovascular clocks. Yale J Biol Med. 2019;92:283-290

Anea CB, Merloiu AM, Fulton DJR, Patel V, Rudic RD. Immunohistochemistry of the circadian clock in mouse and human vascular tissues. Vessel plus. 2018;2

Shang X, Pati P, Anea CB, Fulton DJ, Rudic RD. Differential regulation of bmal1, clock, and endothelial signaling in the aortic arch and ligated common carotid artery. Journal of vascular research. 2016;53:269-278

Cheng B, Anea CB, Yao L, Chen F, Patel V, Merloiu A, Pati P, Caldwell RW, Fulton DJ, Rudic RD. Tissue-intrinsic dysfunction of circadian clock confers transplant arteriosclerosis. Proceedings of the National Academy of Sciences of the United States of America. 2011;108:17147-17152

Anea CB, Zhang M, Stepp DW, Simkins GB, Reed G, Fulton DJ, Rudic RD. Vascular disease in mice with a dysfunctional circadian clock. Circulation. 2009;119:1510-1517


Complete List of Published Work in MyBibliography